Jubilant Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.jubilanttx.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Locally Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2022-03-07
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Jubilant Therapeutics Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT05268666
- Locations
- 🇺🇸
Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States
🇺🇸The Christ Hospital, Cincinnati, Ohio, United States
🇺🇸Tennessee Oncology, PLLC, Nashville, Tennessee, United States
News
Jubilant Therapeutics Initiates Global Clinical Trials for JBI-802 and JBI-778 in Oncology
Jubilant Therapeutics has dosed the first patients in Phase I/II trials for JBI-802, targeting heme-oncology indications, showcasing their commitment to innovative cancer treatments.
Jubilant Therapeutics Initiates Clinical Trials for JBI-802 and JBI-778 in Oncology
Jubilant Therapeutics has dosed the first patients in global clinical trials for JBI-802, a first-in-class CoREST inhibitor, targeting heme-oncology malignancies.